CD4 and neoplasm: 1) Expanded TILs were predominantly CD8+ T cells in 2 patients, and CD4+ T cells in 1 patient 2) Patient 1: lesions remained stable for 9.3 months after TIL infusion. Patient 2: discontinued treatment due to pain. Patient 3: experienced short-term tumor regression